AngioDynamics, a provider of innovative,
minimally invasive medical devices for vascular
access, surgery, peripheral vascular
disease and oncology, announced the launch
of the Bioflo midline catheter indicated for
short-term intravenous therapies.
The US Food and Drug Administration
granted 510(k) clearance for the Bioflo
midline catheter earlier this year.
The catheter often delivers the same
medications, including a variety of antibiotics,
as a peripheral intravenous catheter
(PIV), the company said. However, midlines
can provide access for up to 30 days while
PIVs typically need to be replaced every
couple of days, usually due to performance
failure. Midline catheters are ideal for patients
who may require more than five days
of intravenous therapy.
“The BioFlo midline catheter is a logical
extension of the BioFlo product line,
bringing the clinically relevant thrombus
reduction properties to patients needing
shorter term vascular access to deliver
infusion therapies,” said Chuck Greiner,
AngioDynamics senior vice president, global
franchise leader. “Its increased period of
functionality improves patient satisfaction
by lowering the number of needle sticks
and interruptions to treatment. Similarly,
it offers health care providers an expanded
range of patient treatment options that help
to increase staff efficiency and reduce the
overall cost of care.”
The BioFlo midline catheter with Endexo Technology is indicated for short-term or up
to 30-days of peripheral access to the venous
system for intravenous therapy, including
but not limited to the administration of fluids,
medications and nutrients; the sampling
of blood and for power injections of contrast
media, the company said.
“BioFlo product line sales grew at a
double digit rate last fiscal year and the midline’s
launch, along with continued account
wins and market penetration, position us for
additional solid BioFlo growth this fiscal
year,” said Joseph M. DeVivo, AngioDynamics’
president and chief executive officer.
Officials said BioFlo technology is not a
coating or impregnated into the catheter.
Instead, the Endexo technology polymer
is added directly to the base polyurethane
during the manufacturing process. Endexo
technology is present throughout the catheter
material, including the outer surface,
inner surface and even the cut catheter tip.
Endexo Technology is a proprietary polymer
that is present throughout the catheter
shaft material and remains present for the
life of the catheter, providing long-term
AngioDynamics Inc. product lines include
ablation systems, fluid management
systems, vascular access products,
angiographic products and accessories,
angioplasty products, drainage products,
thrombolytic products and venous products.
More information is available at www.Angio-Dynamics.com.